For patients with metastatic pancreatic ductal adenocarcinoma (PDAC), new clinical data suggest that daraxonrasib—a once‑daily oral drug targeting RAS‑driven tumors—may offer a substantial improvement in survival compared with standard chemotherapy.
What these new results show
In the global, randomized Phase 3 RASolute 302 trial, daraxonrasib was tested in patients with previously treated metastatic PDAC. Key findings include:
- Median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard intravenous chemotherapy (hazard ratio 0.40, p < 0.0001).
- Statistically significant improvements in both progression‑free survival (PFS) and overall survival (OS), meeting all primary and key secondary endpoints.
- A manageable safety profile with no new or unexpected side effects, and most treatment‑related adverse events were mild to moderate and controllable.
“Our trial results indicate that daraxonrasib provides a clear and highly meaningful step forward for patients whose cancer has progressed after prior treatment,” said Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School and principal investigator of RASolute 302. “I expect this could become a practice‑changing option for patients with previously treated metastatic pancreatic cancer.”
Why RAS‑targeting matters in pancreatic cancer
Over 90% of pancreatic cancers are driven by mutations in RAS proteins, which have long been considered “undruggable.” Daraxonrasib is a multi‑selective inhibitor of RAS(ON) proteins, designed to block a broad range of RAS variants (including G12D, G12V, and G12R) that fuel aggressive tumor growth. The RASolute 302 trial enrolled patients with a wide range of RAS variants, as well as those without a known RAS mutation, to capture how the drug works across different tumor genotypes.
The company plans to submit these data to the U.S. Food and Drug Administration and other global regulators as part of a future New Drug Application, and to present detailed results at the 2026 American Society of Clinical Oncology Annual Meeting.
How this fits into ongoing research
Earlier phase data showed that daraxonrasib, taken as a daily pill in patients whose pancreatic cancer had already been treated, led to:
- Tumor shrinkage in about 29–35% of patients, with over 90% achieving disease control.
- Median survival ranging from 13 to nearly 16 months, compared with the typical 7–8 months seen with standard chemotherapy alone.
Because of these encouraging outcomes, a new global Phase 3 RASolute 303 trial is launching to test daraxonrasib both alone and in combination with standard chemotherapy in people recently diagnosed with metastatic PDAC. That study will randomly assign patients to:
- Daraxonrasib monotherapy,
- Daraxonrasib plus chemotherapy (gemcitabine/nab‑paclitaxel), or
- Chemotherapy alone,
to see whether RAS‑targeted therapy can improve survival and disease control in earlier‑line treatment.
What this means for patients
Metastatic pancreatic cancer remains a challenging disease, but the RASolute 302 findings suggest that RAS‑targeted therapy may finally offer a meaningful survival benefit over standard chemotherapy for patients who have already tried prior treatment. For people newly diagnosed with metastatic PDAC, the upcoming RASolute 303 trial provides an opportunity to access this investigational drug in combination with or instead of standard chemo.
Patients and families should discuss with their oncology team whether they might be eligible for daraxonrasib trials or other RAS‑targeted approaches, and periodically check for updates on regulatory decisions that could make this therapy available outside of clinical research.
About Daraxonrasib
Daraxonrasib is a multi‑selective RAS(ON) inhibitor, which means it is designed to bind to and shut down RAS proteins when they are in their active “ON” state, rather than targeting a single specific mutation. By inhibiting multiple active RAS variants (including common G12 mutations such as G12D, G12V, and G12R), daraxonrasib aims to block key growth and survival signals inside pancreatic cancer cells, potentially slowing tumor progression and extending survival across a broad range of RAS‑driven tumors.
Disclaimer: These results come from a company press release and, as of now, have not yet been peer‑reviewed. Patients and caregivers should view the findings as promising but preliminary, and discuss them with their oncology team, who can help interpret how this evolving information may apply to individual care.
